Zevra Therapeutics (ZVRA) legal chief granted RSUs, options and sells stock

Rhea-AI Filing Summary

Zevra Therapeutics insider Rahsaan W. Thompson, the Chief Legal & Compliance Officer and Secretary, reported multiple equity transactions in late January 2026. On January 29, he received 37,500 restricted stock units, which start vesting on January 29, 2027 in yearly installments, and a stock option for 75,000 shares at $8.86 per share that vests over four years and expires in 2036.

On January 30, one third of a prior restricted stock unit grant, or 11,333 units, vested and converted into common shares. The same day, he sold 4,080 common shares at a weighted average price of $8.8259 under a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2025, leaving him with 49,919 common shares held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thompson Rahsaan

(Last) (First) (Middle)

C/O ZEVRA THERAPEUTICS, INC.

1180 CELEBRATION BOULEVARD, SUITE 103

(Street)

CELEBRATION FL 34747

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ZEVRA THERAPEUTICS, INC. [ ZVRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)	X	Other (specify below)
	Chief Legal & Compliance		Secretary

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/30/2026		M		11,333	A	(1)	53,999	D
Common Stock	01/30/2026		S(2)		4,080	D	$8.8259(3)	49,919	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	01/29/2026		A		37,500		(4)	(4)	Common Stock	37,500	$0	37,500	D
Stock Option (right to buy)	$8.86	01/29/2026		A		75,000		(5)	01/28/2036	Common Stock	75,000	$0	75,000	D
Restricted Stock Unit	(1)	01/30/2026		M			11,333	(6)	(6)	Common Stock	11,333	$0	22,667	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

2. Adoption date of referenced 10b5-1(c) plan is: 3/27/2025.

3. This transaction was executed in multiple trades at prices ranging from $8.58 to $9.04. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

4. The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date.

5. Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

6. One third of the restricted stock units vested and settled on January 30, 2026. The remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting Person's continued service through such vesting date.

Remarks:

	/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Rahsaan W. Thompson	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ZVRA executive Rahsaan Thompson report?

Rahsaan Thompson reported new equity awards and share activity. He received 37,500 restricted stock units and a 75,000-share stock option, had 11,333 restricted stock units vest into common shares, and sold 4,080 common shares in a planned trade at a weighted average price of $8.8259.

How many Zevra Therapeutics (ZVRA) shares did the insider sell and at what price?

He sold 4,080 shares of Zevra Therapeutics common stock. The sale used multiple trades, with a weighted average price of $8.8259 per share, across an execution range from $8.58 to $9.04, as disclosed in the weighted average price footnote.

Was the ZVRA insider stock sale under a 10b5-1 trading plan?

Yes. The reported sale of 4,080 Zevra Therapeutics common shares was executed under a Rule 10b5-1(c) trading plan. The company states the referenced plan was adopted on March 27, 2025, indicating the sale followed a pre-established trading arrangement.

What new restricted stock units did the ZVRA officer receive in January 2026?

On January 29, 2026, he received 37,500 restricted stock units. One third will vest and settle on January 29, 2027, and the remaining two thirds will vest and settle in equal annual installments thereafter, conditioned on his continued service through each vesting date.

What are the terms of the new ZVRA stock option grant to Rahsaan Thompson?

He received a stock option covering 75,000 shares at an exercise price of $8.86. Granted under the Amended and Restated 2014 Equity Incentive Plan, the option vests in four equal annual installments beginning one year after the grant date and expires on January 28, 2036.

How many Zevra Therapeutics shares does the insider hold after these transactions?

After the January 30, 2026 transactions, he directly holds 49,919 shares of Zevra Therapeutics common stock. In addition, he beneficially owns derivative interests, including 37,500 restricted stock units and a 75,000-share stock option granted under the company’s equity incentive plan.